title: [Statement of the Polish Gynecological Society Expert Group on the use of Macmiror Complex 500].
abstract: The group of experts representing the Polish Gynecologic Society has issued this statement based on the review of available literature on the potential benefits of the use of Macmiror Complex 500 in obstetrical and gynecologic practice. Mixed Vaginitis (MV) eg. the vaginal infection caused by at least two out of the triad of pathogens (fungi, bacteria and Trichomonas Vaginalis [TV]), constitutes the type of vaginitis which is underestimated as for its prevalence. Mixed pathogens are responsible for as much as one third of all vaginal infections. Macmiror Complex 500 contains two active ingredients: nifuratel and nystatin. Macmiror Complex 500 affects all common causes of vulvovaginitis, i.e. bacteria, yeasts and TV. At the same time, it is not effective against Lactobacillus spp., which is a clear advantage in the treatment of vaginal infections. The antibacterial spectrum of nifuratel includes aerobic and anaerobic bacteria. Moreover nifuratel is effective against Chlamydia trachomatis and Mycoplasma spp., it has an anti-trichomonal effect comparable to metranidazole and shows certain activity against Candida spp. Nystatin is effective against Candida albicans and is even very effective against Candida glabrata which is usually more resistant to imidazole antifungal agents. Nystatin's importance is rising due to the current increase of candidoses caused by non-albicans types. This increase is especially perceptible in recurring candidoses. The review of the available literature on the effectiveness of Macmiror Complex 500 in the OB/GYN practice leads to the following conclusions: the exeptionally broad antibacterial and antifungal and trichomonicidal activity of this formulation makes it a drug of choice in cases where MV is suspected. The possibility to treat both partners, favorable safety profile in pregnant patients and the availability of both vaginal ovules and the cream with applicator makes this drug an effective and suitable treatment option in obstetrical and gynecologic practice.
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D000994:Antitrichomonal Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006176:Gynecology / Q000592:standards; D006801:Humans; D009313:National Health Programs / Q000592:standards; D009545:Nifuratel / Q000627:therapeutic use*; D009761:Nystatin / Q000008:administration & dosage; D009774:Obstetrics / Q000592:standards; D011044:Poland; D011247:Pregnancy; D011785:Quality Assurance, Health Care / Q000592:standards; D012955:Societies, Medical / Q000592:standards; D014247:Trichomonas Vaginitis / Q000188:drug therapy* / Q000382:microbiology; D014848:Vulvovaginitis / Q000188:drug therapy* / Q000382:microbiology; D016387:Women's Health
chemical_list: D000935:Antifungal Agents; D000994:Antitrichomonal Agents; D004338:Drug Combinations; D009761:Nystatin; D009545:Nifuratel